Aeluma (ALMU) Q2 2026 earnings review
Fortress Balance Sheet, Fragile Margins
Aeluma's Q2 was defined by a massive capital injection rather than operational execution. While the company successfully raised ~$23M, securing a $38.6M cash pile to fund commercialization, core metrics deteriorated. Revenue fell 21% YoY to $1.27M, and Gross Margin collapsed to 27.7% from 63.8% a year ago as the company ramped staffing and operations. Management cites 'initial sales orders' and new leadership as signs of a pivot to commercial products, but the financials currently show a business with rising costs and lumpy, declining contract revenue.
🐂 Bull Case
Cash balance surged to $38.6M (vs $3.6M in June) following a public offering. With trailing 6-month operating cash burn of only ~$1.1M, the company has significant runway to execute its commercialization strategy without immediate solvency risk.
Management confirmed they have begun taking sales orders and receiving price quotes, moving beyond pure R&D contracts. Commissioning of automated wafer probers and new executive hires signal a serious shift toward mass production readiness.
🐻 Bear Case
Gross margins compressed violently to 27.7% in Q2, down from 49.4% in Q1 and 63.8% a year ago. Rising COGS and personnel costs are outpacing revenue, indicating negative operating leverage during this scaling phase.
Despite the narrative of growth and 'ramping engagements,' revenue has declined sequentially and YoY. The business remains dependent on lumpy R&D contracts, and product revenue has yet to make a material impact on the top line.
⚖️ Verdict: ⚪
Neutral. The capital raise is a game-changer for stability, buying Aeluma time. However, the operational deterioration—specifically the sharp drop in margins and revenue—raises questions about the unit economics of their commercial ramp. Proof of product adoption is needed to justify higher costs.
Key Themes
Gross Margin Compression
Profitability at the gross level took a severe hit. Gross margin fell to 27.7% in Q2, a stark contrast to the ~64% seen in 25Q2 and ~49% in 26Q1. This suggests that as Aeluma scales operations and headcount (COGS $0.92M vs $0.58M YoY), they are incurring significant fixed costs not yet covered by volume, or that the mix of revenue is shifting to lower-margin activities.
Capital Injection Extends Runway
The most positive development is the balance sheet. Cash and equivalents jumped to $38.6M from $15.7M at FY25 year-end, primarily due to $23.4M in net proceeds from a public offering. Given the net cash used in operating activities was only $1.1M for the first six months of FY26, Aeluma is well-capitalized to withstand R&D lumpiness.
Transition from R&D to Product
The narrative is shifting from 'development' to 'delivery.' The company highlighted the installation of automated wafer probers and the receipt of initial (albeit small) sales orders. This transition is critical: current revenue is still 'primarily' R&D contracts. Investors should watch for the crossover point where product sales become the majority revenue driver.
Operating Expenses Ramping
Operating expenses rose to $3.35M from $2.99M in Q1 and $1.22M YoY. Specifically, R&D expense more than doubled sequentially ($0.61M vs $0.27M). While necessary for growth, this increased burn rate combined with lower gross margins widened the operating loss to $2.1M (vs $1.6M in Q1).
Strategic Partnerships & Validation
Third-party validation remains a key asset. New contracts with NASA (quantum) and funding from RFSUNY, plus membership in the MMEC consortium, provide both non-dilutive funding and technical credibility. These partnerships anchor the technology while commercial markets (mobile, data centers) develop.
Other KPIs
Reversing. Deteriorated from a gain of $0.65M in the prior year period and a loss of $0.45M in the prior quarter. The shift to negative EBITDA reflects the investment phase in personnel and capacity ahead of recognized product revenue.
Stable/Widening. The loss widened sequentially from -$1.49M in Q1, driven by lower revenue and higher OpEx. However, it improved vs -$2.9M in 25Q2, though the prior year figure included significant noise from derivative liability changes.
Accelerating. Up significantly from $0.27M in Q1. This spike indicates a push in development activity, likely related to the new NASA contract and quantum dot laser integration efforts.
Guidance
Decelerating (Implied). Aeluma generated $2.66M in H1. To reach the midpoint ($5.0M), H2 revenue needs to be ~$2.34M, which implies a decline compared to H1. Reaffirming this range suggests management does not expect a massive immediate hockey-stick ramp in H2.
Stable. The company maintained its target for new development contracts. These are critical for near-term cash flow ('non-dilutive funding') while product revenue scales.
Key Questions
Gross Margin Recovery
Gross margins collapsed to roughly 28% this quarter. Is this a structural reset due to new manufacturing overhead, or a temporary mix issue? When should we expect margins to return to the 50%+ range?
Product Revenue Timeline
You mentioned receiving 'initial orders' and requests for quotes. When do you expect product revenue to materially separate from R&D contract revenue—is this an H2 FY26 story or FY27?
Implied H2 Deceleration
Your reaffirmed guidance implies H2 revenue could be lower than H1. What factors (contract timing, seasonality) would cause revenue to step down or stay flat in the second half despite your commercialization efforts?